Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level

Chinese Medical Journal

Volumn 109, Issue 12, 1996, Pages 933-936

  Guo, Ruichen ^a   Thormann, Wolfgang ^b   Lauterberg, Bernhard ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DAPSONE; DRUG METABOLITE; GLUTATHIONE;

ACETYLATOR PHENOTYPE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; LYMPHOCYTE; MALE; SIDE EFFECT;

ACETYLATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-INFECTIVE AGENTS; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPSONE; FEMALE; GLUTATHIONE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PHENOTYPE;

EID: 0030499294     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Leoung GS, Mills J, Hopewell PC, et al. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:45.
2. Poulsen A, Hultburg B, Thomsen K, et al. Regression of Kaposi's sarcoma in AIDS after treatment with dapsone. Lancet 1984; 1:560.
3. Lee BL, Moore L, Wilson M, et al. Increased prevalence of slow acetylator status in patients with acquired immunodeficiency syndrome. Abstr papers 1990; 2(51):183.
4. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total oxidized glutathione. Anal Biochem 1969; 27:502.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248.
6. Guo R, Thormann W. Acetylator phenotyping via analysis of four caffeine metabolites in human urine by micellar electrokinetic capillary chromatography with multiwavelength detection. Electrophoresis 1993; 14:547.
7. Guo R, Thormann W. Analysis of four caffeine metabolites in human urine by Micellar Electrokinetic Capillary Chromatography with multiwavelength detection for N-acetylator Phenotyping. ACTA Academiae Medicinae [Shandong] 1995; 1:73.
8. Aebi S, Assereto R, Lauterburg BH. High dose intravenous glutathione in man, pharmacokinetics and effects on cysteine in plasma and urine. Eur J Clin Invest 1991; 21:103.
9. Newton GL, Dorian R, Fahey RC. Analysts of biological thiols: derivatization with monobromobimane and separation by reverse-phase high performance liquid chromatography. Anal Biochem 1981; 114:383.
10. Clark DWJ. Genetically determined variability in acetylation and oxidation-therapeutic implications. Drugs 1985; 29:342.
11. Rieder MJ, Shear NH, Kance A, et al. Prominence of slow acetylate phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 1:13.
12. Buhl R, Holroyd KJ, Mastrangeli A, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 11:1294.
13. Eck HP, Gmunder H, Hartmann M, et al. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler 1989; 370:101.
14. Burgunder JM, Varriale A, Lauterburg BH. Effects of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989; 36:127.